Adherence evaluation of osteoporosis treatment

{"level_sex_clusion_I":[{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Woman; Over the age of 50 years; Patient to whom has been prescribed one of the following osteoporosis treatments in the six months prior to the inclusion starting date: bisphosphonates, selective estrogen receptor modulators (SERM), or strontium ranelate; Patient fluent in French and who has the cognitive and functional ability required to complete the self-questionnaires included in the study on their own; Informed patient who has given their oral consent to participate in this study","clusion_E":""}